Table 2.
Reported cases of MN induced by D-penicillamine associated with crescent formation evaluated for ANCA
| Year | Initial diagnosis | Clinical manifestation | IF study (capillary wall) | MN stage | ANCA | Outcome | Treatment | Reference |
| 1993 | RA | RPGN | Granular IgG, IgA, C3 | NR | negative | improved | prednisolone, cyclophosphamide, plasma exchange | 15 |
| 1995 | RA | PRS | Granular IgG, C3 | NR | P-ANCA+, MPO-ANCA+ | ESRD | prednisolone, cyclophosphamide, plasma exchange | 16 |
| 1996 | RA | RPGN | Granular IgG, C3 | II | P-ANCA + | improved | prednisolone, cyclophosphamide, azathioprine | 17 |
| 1997 | SSc | RPGN | Granular IgG, C3 | II–III | P-ANCA+, MPO-ANCA+ | improved | prednisolone, cyclophosphamide, hemodialysis | 18 |
RA = rheumatoid arthritis; NR = not reported; PRS = pulmonary renal syndrome; P-ANCA = perinuclear ANCA; ESRD = end-stage renal disease; SSc = systemic sclerosis.